MX341020B - Peptidos derivados de lactoferrina humana y su uso. - Google Patents

Peptidos derivados de lactoferrina humana y su uso.

Info

Publication number
MX341020B
MX341020B MX2013007995A MX2013007995A MX341020B MX 341020 B MX341020 B MX 341020B MX 2013007995 A MX2013007995 A MX 2013007995A MX 2013007995 A MX2013007995 A MX 2013007995A MX 341020 B MX341020 B MX 341020B
Authority
MX
Mexico
Prior art keywords
derived peptides
human lactoferrin
lactoferrin derived
human
peptides
Prior art date
Application number
MX2013007995A
Other languages
English (en)
Other versions
MX2013007995A (es
Inventor
Walse Björn
Mahlapuu Margit
Svensson Bo
Björn Camilla
Sjöstrand Veronika
Original Assignee
Pergamum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pergamum Ab filed Critical Pergamum Ab
Publication of MX2013007995A publication Critical patent/MX2013007995A/es
Publication of MX341020B publication Critical patent/MX341020B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a los nuevos péptidos y al uso de los mismos, en particular para el tratamiento y/o prevención de infecciones, inflamaciones, dolor, heridas, cicatrices y/o tumores.
MX2013007995A 2011-01-26 2012-01-25 Peptidos derivados de lactoferrina humana y su uso. MX341020B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11152213A EP2481751A1 (en) 2011-01-26 2011-01-26 Human lactoferrin derived peptides
PCT/EP2012/051112 WO2012101157A1 (en) 2011-01-26 2012-01-25 Human lactoferrin derived peptides and there use

Publications (2)

Publication Number Publication Date
MX2013007995A MX2013007995A (es) 2013-12-02
MX341020B true MX341020B (es) 2016-08-04

Family

ID=44123487

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013007995A MX341020B (es) 2011-01-26 2012-01-25 Peptidos derivados de lactoferrina humana y su uso.
MX2013008530A MX342313B (es) 2011-01-26 2012-01-25 Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013008530A MX342313B (es) 2011-01-26 2012-01-25 Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.

Country Status (13)

Country Link
US (2) US8846608B2 (es)
EP (3) EP2481751A1 (es)
JP (2) JP6158712B2 (es)
KR (2) KR101933900B1 (es)
CN (2) CN103476792B (es)
AU (2) AU2012210565B2 (es)
BR (2) BR112013018365A2 (es)
CA (2) CA2825247A1 (es)
ES (2) ES2633353T3 (es)
MX (2) MX341020B (es)
PL (1) PL2668205T3 (es)
RU (2) RU2596393C2 (es)
WO (2) WO2012101157A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481751A1 (en) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
GB201401877D0 (en) * 2014-02-04 2014-03-19 Univ Tromsoe Peptides
CN104888202A (zh) * 2014-05-22 2015-09-09 闫牧乔 一种治疗扁桃体炎的药物
IT201800002457A1 (it) * 2018-02-07 2019-08-07 Neilos S R L Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie
RU2681310C1 (ru) * 2018-09-05 2019-03-06 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ первичной хирургической обработки инфицированных ран кожи и мягких тканей с использованием пептида Gly-His-Lys-D-Ala
RU2681216C1 (ru) * 2018-09-05 2019-03-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ стимуляции регенерации инфицированных ран кожи и мягких тканей с применением пептида Gly-His-Lys-D-Ala
KR102032945B1 (ko) * 2018-12-03 2019-10-16 순천대학교 산학협력단 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물
NL2024839B1 (en) * 2020-02-05 2021-09-13 Cbmr Scient Nanoscience B V Antimicrobial peptide for treatment and controlling skin disorders relating to microbial infection

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2818056B2 (ja) 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
EP0629347B1 (en) 1992-01-23 1997-07-02 Morinaga Milk Industry Co., Ltd. Antibacterial agent and treatment of article therewith
JP3347819B2 (ja) 1993-06-28 2002-11-20 森永乳業株式会社 抗菌性ペプチドの精製方法
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
JP3529423B2 (ja) 1994-04-01 2004-05-24 森永乳業株式会社 抗菌性ペプチドの製造方法
JP3812957B2 (ja) 1994-08-02 2006-08-23 森永乳業株式会社 角膜損傷治療剤
JPH08143468A (ja) 1994-11-17 1996-06-04 Morinaga Milk Ind Co Ltd 抗潰瘍剤
WO1998006425A1 (en) 1996-08-12 1998-02-19 A+ Science Invest Ab Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
SE9804614A0 (en) * 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
JP2002544210A (ja) * 1999-05-14 2002-12-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 炎症で仲介される感染症に対する抗炎症性治療方法
CA2388910C (en) 1999-11-11 2008-10-07 Am-Pharma B.V. Antimicrobial activity of the first cationic cluster of human lactoferrin
RU2165769C1 (ru) * 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
SE0102067D0 (sv) * 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
WO2006047744A2 (en) 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
US7960339B2 (en) * 2006-07-10 2011-06-14 Österreichische Akademie der Wissenschaften Antimicrobial peptides
WO2008096814A1 (ja) 2007-02-09 2008-08-14 Genomidea Inc. 新規ポリペプチド及びそれを有効成分として含有する抗菌剤
WO2008096816A1 (ja) 2007-02-09 2008-08-14 Genomidea Inc. 血管新生誘導剤及びそれに用いられるポリペプチド
EP2050461A1 (en) 2007-10-19 2009-04-22 PharmaSurgics in Sweden AB Peptides based on the sequence of human lactoferrin and their use
EP2060586A1 (en) * 2007-11-14 2009-05-20 PharmaSurgics in Sweden AB New synthetic arginine substituted peptides and their use
JP5524049B2 (ja) * 2008-05-23 2014-06-18 第一三共株式会社 目的ペプチドの血漿中半減期延長作用を有するペプチド
RU2501566C2 (ru) * 2009-01-13 2013-12-20 Пергамум АБ Новые фармацевтические композиции
EP2481751A1 (en) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
KR101341210B1 (ko) * 2013-01-24 2013-12-12 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 신규한 항균 펩타이드 및 이의 용도

Also Published As

Publication number Publication date
ES2645959T3 (es) 2017-12-11
US8846608B2 (en) 2014-09-30
EP2668204A2 (en) 2013-12-04
RU2013139294A (ru) 2015-03-10
JP2014505061A (ja) 2014-02-27
KR20140026367A (ko) 2014-03-05
US9132165B2 (en) 2015-09-15
EP2668204B1 (en) 2017-09-27
WO2012101157A1 (en) 2012-08-02
CA2825247A1 (en) 2012-08-02
KR20140020252A (ko) 2014-02-18
JP2014505062A (ja) 2014-02-27
ES2633353T3 (es) 2017-09-20
WO2012101156A3 (en) 2013-05-30
CN103459419A (zh) 2013-12-18
RU2013139302A (ru) 2015-03-10
PL2668205T3 (pl) 2017-09-29
CN103476792B (zh) 2015-11-25
CN103476792A (zh) 2013-12-25
KR101949210B1 (ko) 2019-02-18
US20140031296A1 (en) 2014-01-30
WO2012101156A2 (en) 2012-08-02
US20130310306A1 (en) 2013-11-21
JP6158712B2 (ja) 2017-07-05
KR101933900B1 (ko) 2018-12-31
EP2481751A1 (en) 2012-08-01
CN103459419B (zh) 2016-05-11
AU2012210564B2 (en) 2016-10-27
AU2012210565B2 (en) 2017-03-30
MX2013008530A (es) 2013-12-09
EP2668205A1 (en) 2013-12-04
CA2825246A1 (en) 2012-08-02
BR112013018264A2 (pt) 2016-08-30
MX342313B (es) 2016-09-26
RU2596393C2 (ru) 2016-09-10
RU2593757C2 (ru) 2016-08-10
MX2013007995A (es) 2013-12-02
BR112013018365A2 (pt) 2016-08-30
EP2668205B1 (en) 2017-05-10
JP6158713B2 (ja) 2017-07-05

Similar Documents

Publication Publication Date Title
MX2013007995A (es) Peptidos derivados de lactoferrina humana y su uso.
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
WO2015009726A3 (en) Medical uses of cd38 agonists
MY158992A (en) Forms of rifaximin and uses thereof
PH12014501702A1 (en) Imidazopyrrolidinone compounds
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
UA107706C2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
AU2011328009A8 (en) Compounds and methods for treating pain
PH12015500186A1 (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
TW201611843A (en) Methods of treatment with arginine deiminase
MX2013006140A (es) Uso de ligandos sigma en dolor por cancer de huesos.
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
WO2013174774A3 (en) Cosmetic compositions comprising magnetosomes and uses thereof
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
MX2016007626A (es) Peptido antimicrobiano y usos del mismo.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma

Legal Events

Date Code Title Description
FG Grant or registration